🇺🇸 FDA
Pipeline program

FX006 32 mg

FX006-2017-013

Phase 2 small_molecule completed

Quick answer

FX006 32 mg for Osteoarthritis of the Shoulder is a Phase 2 program (small_molecule) at Pacira BioSciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Pacira BioSciences
Indication
Osteoarthritis of the Shoulder
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials